BOCCI, GUIDO
BOCCI, GUIDO
Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase
2023 Tinivella, A.; Banchi, M.; Gambacorta, G.; Borghi, F.; Orlandi, P.; Baxendale, I. R.; Di Paolo, A.; Bocci, G.; Pinzi, L.; Rastelli, G.
In vivo and in situ monitoring of doxorubicin pharmacokinetics with an implantable bioresorbable optical sensor.
2025 Corsi, M; Maurina, E; Surdo, S; Vandini, E; Daini, E; Vilella, A; Leo, G; Farshchian, M; Grisendi, G; Golinelli, G; Dominici, M; Bocci, G; Giuliani, D; Barillaro, G.
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib.
2024 Orlandi, P; Banchi, M; Vaglini, F; Carli, M; Aringhieri, S; Bandini, A; Pardini, C; Viaggi, C; Lai, M; Alì, G; Ottani, A; Vandini, E; Guidi, P; Bernardeschi, M; La Rocca, V; Francia, G; Fontanini, G; Pistello, M; Frenzilli, G; Giuliani, D; Scarselli, M; Bocci, G.
Melanocortin receptor-4 and glioblastoma cells: effects of the selective antagonist ML00253764 alone and in combination with temozolomide on cell proliferation and apoptosis.
2018 Vaglini, F; Pardini, C; Di Desidero, T; Orlandi, P; Pasqualetti, F; Ottani, A; Giuliani, D; Guarini, S; Bocci, G
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo.
2025 Bandini, A; Banchi, M; Orlandi, P; Vaglini, F; Alì, G; Fontanini, G; Ottani, A; Giuliani, D; Vandini, E; Francia, G; Carli, M; Scarselli, M; Bocci, G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase | 1-gen-2023 | Tinivella, A.; Banchi, M.; Gambacorta, G.; Borghi, F.; Orlandi, P.; Baxendale, I. R.; Di Paolo, A.; Bocci, G.; Pinzi, L.; Rastelli, G. | |
| In vivo and in situ monitoring of doxorubicin pharmacokinetics with an implantable bioresorbable optical sensor. | 1-gen-2025 | Corsi, M; Maurina, E; Surdo, S; Vandini, E; Daini, E; Vilella, A; Leo, G; Farshchian, M; Grisendi, G; Golinelli, G; Dominici, M; Bocci, G; Giuliani, D; Barillaro, G. | |
| Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib. | 1-gen-2024 | Orlandi, P; Banchi, M; Vaglini, F; Carli, M; Aringhieri, S; Bandini, A; Pardini, C; Viaggi, C; Lai, M; Alì, G; Ottani, A; Vandini, E; Guidi, P; Bernardeschi, M; La Rocca, V; Francia, G; Fontanini, G; Pistello, M; Frenzilli, G; Giuliani, D; Scarselli, M; Bocci, G. | |
| Melanocortin receptor-4 and glioblastoma cells: effects of the selective antagonist ML00253764 alone and in combination with temozolomide on cell proliferation and apoptosis. | 1-gen-2018 | Vaglini, F; Pardini, C; Di Desidero, T; Orlandi, P; Pasqualetti, F; Ottani, A; Giuliani, D; Guarini, S; Bocci, G | |
| Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo. | 1-gen-2025 | Bandini, A; Banchi, M; Orlandi, P; Vaglini, F; Alì, G; Fontanini, G; Ottani, A; Giuliani, D; Vandini, E; Francia, G; Carli, M; Scarselli, M; Bocci, G |